Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Filing Names

Medivir Ab
Medivir Ab_20100107

Medivir Ab patents

Recent patent applications related to Medivir Ab. Medivir Ab is listed as an Agent/Assignee. Note: Medivir Ab may have other listings under different names/spellings. We're not affiliated with Medivir Ab, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medivir Ab-related inventors

Date Medivir Ab patents (updated weekly) - BOOKMARK this page
09/28/17Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
09/21/17Dioxolane analogues of uridine for the treatment of cancer
08/10/17Macrocyclic inhibitors of hepatitis c virus
07/13/17Hcv ns-3 serine protease inhibitors
06/15/17Protease inhibitors
04/27/17Treatment of chagas disease
04/20/17Hcv polymerase inhibitors
11/24/16Hcv polymerase inhibitors
09/22/16Hcv polymerase inhibitors
09/22/16Respiratory syncytial virus inhibitors
08/18/16Macrocyclic inhibitors of hepatitis c virus
07/07/16Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor
03/10/16Protease inhibitors
08/06/15Macrocyclic inhibitors of hepatitis c virus
06/25/15Hcv polymerase inhibitors
09/11/14Macrocyclic inhibitors of hepatitis c virus
08/07/14Protease inhibitors
03/06/14Hcv polymerase inhibitors
09/05/13Protease inhibitors
08/22/13Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350
06/06/13Hcv polymerase inhibitors
11/15/12Protease inhibitors
08/30/12Cysteine protease inhibitors
05/17/12Acyclic nucleoside derivatives
05/10/12Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350
01/19/12(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
09/22/11Uracyl cyclopropyl nucleotides
07/14/11Antiviral nucleosides
05/12/11Cysteine protease inhibitors
05/12/111-[2', 3' -dideoxy-3' c- (hydroxymethyl) - beta-d-erythro-pentofuranosyl] cytosine derivatives as hiv inhibitors
05/05/11Cysteine protease inhibitors
04/21/11Cyclopropyl polymerase inhibitors
02/17/11Protease inhibitors
01/27/11Dutpase inhibitors
01/20/11Antiviral nucleosides
07/01/10Hcv ns-3 serine protease inhibitors
05/27/10Antiviral nucleosides
03/25/10Dutpase inhibitors
01/07/10Hcv ns-3 serine protease inhibitors
11/12/09Macrocyclic inhibitors of hepatitis c virus
10/29/09Antiviral formulation
08/27/09(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
03/19/09Acyclic nucleoside derivatives
01/07/10Hcv ns-3 serine protease inhibitors

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Medivir Ab in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medivir Ab with additional patents listed. Browse our Agent directory for other possible listings. Page by